Recommended Topic Related To:

Vaqta

"The U.S. Food and Drug Administration (FDA) continues its investigation of acute hepatitis illnesses linked to products labeled OxyElite Pro.

FDA advises consumers not to use any dietary supplements labeled OxyElite Pro or VERSA-1 becau"...

Vaqta

Indications
Dosage
How Supplied

INDICATIONS

Indications And Use

VAQTA® [Hepatitis A Vaccine, Inactivated] is indicated for the prevention of disease caused by hepatitis A virus (HAV) in persons 12 months of age and older. The primary dose should be given at least 2 weeks prior to expected exposure to HAV.

DOSAGE AND ADMINISTRATION

FOR INTRAMUSCULAR ADMINISTRATION ONLY.

Dosage And Schedule

Children/Adolescents (12 months through 18 years of age)

The vaccination schedule consists of a primary 0.5-mL dose administered intramuscularly, and a 0.5-mL booster dose administered intramuscularly 6 to 18 months later.

Adults (19 years of age and older)

The vaccination schedule consists of a primary 1-mL dose administered intramuscularly, and a 1-mL booster dose administered intramuscularly 6 to 18 months later.

Booster Immunization Following Another Manufacturer's Hepatitis A Vaccine

A booster dose of VAQTA may be given at 6 to 12 months following a primary dose of HAVRIX [see Clinical Studies].

Preparation And Administration

Shake the single-dose vial or single-dose prefilled syringe well to obtain a slightly opaque, white suspension before withdrawal and use. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Discard if the suspension does not appear homogenous or if extraneous particulate matter remains or discoloration is observed.

For single-dose vials, withdraw and administer entire dose of VAQTA intramuscularly using a sterile needle and syringe.

For single-dose prefilled syringes, securely attach a needle by twisting in a clockwise direction and administer dose of VAQTA intramuscularly.

For adults, adolescents, and children older than 2 years of age, the deltoid muscle is the preferred site for intramuscular injection. For children 12 through 23 months of age, the anterolateral area of the thigh is the preferred site for intramuscular injection.

HOW SUPPLIED

Dosage Forms And Strengths

Suspension for injection available in four presentations:

  • 0.5-mL pediatric dose in single-dose vials and prefilled syringes
  • 1-mL adult dose in single-dose vials and prefilled syringes

[See DESCRIPTION for listing of vaccine components and Storage and Handling]

Storage And Handling

VAQTA is available in single-dose vials and prefilled Luer-Lok® syringes.

Pediatric/Adolescent Formulations

25U/0.5 mL in single-dose vials and prefilled Luer-Lok® syringes.

NDC 0006-4831-41 – box of ten 0.5-mL single dose vials.
NDC
0006-4095-02 – carton of ten 0.5-mL prefilled single-dose Luer-Lok® syringes with tip caps.
NDC 0006-4095-09 – carton of six 0.5-mL prefilled single-dose Luer-Lok® syringes with tip caps.

Adult Formulations

50U/1-mL in single-dose vials and prefilled Luer-Lok® syringes.

NDC 0006-4841-00 – 1-mL single dose vial.
NDC
0006-4841-41 – box of ten 1-mL single dose vials.
NDC
0006-4096-02 – carton of ten 1-mL prefilled single-dose Luer-Lok® syringes with tip caps.
NDC 0006-4096-09 – carton of six 1-mL prefilled single-dose Luer-Lok® syringes with tip caps.

Store vaccine at 2-8°C (36-46°F).

DO NOT FREEZE since freezing destroys potency.

Manuf. and Dist. by: Merck Sharp & Dohme Corp., a subsidiary of MERCK & CO., INC., Whitehouse Station, NJ 08889, USA. Revised: Feb 2014

Last reviewed on RxList: 8/29/2014
This monograph has been modified to include the generic and brand name in many instances.

Indications
Dosage
How Supplied
A A A

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Living Better

Find the secrets to longer life.